Arax Advisory Partners Sells 135,358 Shares of Merck & Co., Inc. $MRK

Posted by Francis Steltz on Jun 14th, 2026

Arax Advisory Partners decreased its holdings in Merck & Co., Inc. (NYSE:MRK – Free Report) by 31.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 293,929 shares of the company’s stock after selling 135,358 shares during the quarter. Merck & Co., Inc. makes up about 0.9% of Arax Advisory Partners’ investment portfolio, making the stock its 24th largest position. Arax Advisory Partners’ holdings in Merck & Co., Inc. were worth $30,939,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of MRK. Kingdom Financial Group LLC. bought a new position in Merck & Co., Inc. in the 4th quarter valued at $25,000. United Financial Planning Group LLC bought a new position in Merck & Co., Inc. in the 3rd quarter valued at $31,000. High Note Wealth LLC raised its position in Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after purchasing an additional 109 shares during the last quarter. IFC & Insurance Marketing Inc. bought a new position in Merck & Co., Inc. in the 4th quarter valued at $31,000. Finally, Gilpin Wealth Management LLC bought a new position in Merck & Co., Inc. in the 4th quarter valued at $32,000. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Down 1.4%

Shares of Merck & Co., Inc. stock opened at $119.05 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a 12 month low of $76.66 and a 12 month high of $125.14. The business has a fifty day simple moving average of $116.55 and a 200 day simple moving average of $113.23. The stock has a market cap of $294.04 billion, a PE ratio of 33.54, a price-to-earnings-growth ratio of 2.68 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.85 billion. During the same period in the previous year, the firm earned $2.22 earnings per share. The firm’s quarterly revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Research analysts predict that Merck & Co., Inc. will post 5.17 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be paid a dividend of $0.85 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.9%. Merck & Co., Inc.’s payout ratio is 95.77%.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on MRK shares. Wells Fargo & Company cut their price objective on Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Wall Street Zen upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. Barclays started coverage on Merck & Co., Inc. in a research report on Friday, February 20th. They issued an “overweight” rating and a $140.00 price objective for the company. UBS Group lifted their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Finally, JPMorgan Chase & Co. lifted their price objective on Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a research report on Monday, April 6th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $128.18.

View Our Latest Stock Report on MRK

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

Positive Sentiment: Merck Animal Health announced a definitive agreement to acquire TARGAN, a poultry biodevice company, which could strengthen Merck’s animal health division and broaden its technology-driven growth opportunities. Merck Animal Health to Acquire TARGAN
Positive Sentiment: Merck saw unusually heavy call option buying, with traders purchasing 170,441 calls, a sharp jump versus normal volume that often signals bullish expectations from sophisticated investors.
Positive Sentiment: Wells Fargo reiterated a buy rating on Merck, while another article highlighted that Wall Street’s overall bullish view continues to keep MRK on investors’ radar.
Neutral Sentiment: Merck has also been featured in broader market commentary and “most searched” lists, suggesting rising attention rather than a new fundamental catalyst.
Neutral Sentiment: One article noted Merck’s recent trading uptick but said it lagged the broader market, indicating modest price strength rather than a major breakout. Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.